Cervical cancer initially develops in the cervix and affects the same. It then spreads to the vaginal wall, uterus and other parts of the body. Cervical Cancer Diagnostics are tests used to diagnose cervical cancer. The cervical cancer diagnostics market is witnessing huge growth. It is likely to expand at around USD 9 billion by the end of 2020. This is due to the increasing prevalence of cervical cancers in the world.
The factors pertaining to the growth of the cervical cancer diagnostics market are increasing HPV (human papillomavirus) infections, technological improvements and flow in the prevalence of cervical cancers. However, lack of awareness regarding cervical cancers and absence of proper healthcare infrastructure are likely to restrain the cervical cancer diagnostics market.
Download sample Copy of This Report at http://www.grandviewresearch.com/industry-analysis/cervical-cancer-diagnostics-market
The cervical cancer diagnostics market can be bifurcated into tests and geographies. The market, on the basis of tests, can be divided into ECC (endocervical curettage), HPV testing, Pap smear tests colposcopy and LEEP (loop electrosurgical excision procedure).
Pap smear tests dominated the market. They accounted for more than 45 percent of the overall tests market. This was due to low costs, early detection rates and increasing awareness regarding cervical cancers.
Geographically, North America, Asia Pacific, Europe and rest of the world are the major regions for the cervical cancer diagnostics market. North America captured the largest market in 2013. This owed to innovations in technology and patient awareness.
Asia Pacific is observing the fastest growth for the cervical cancer diagnostics market. This is on account of increasing disposable income, growing market penetration and augmented patient awareness. Governmental support in improving healthcare infrastructure is also likely to boost the demand for the cervical cancer diagnostics market.


For more information, visit: http://www.ni2014.org/